Bolt Biotherapeutics Presents Updated Clinical Data From Phase 1 Dose-Escalation Trial Of BDC-1001 As Monotherapy And In Combination With Nivolumab In HER2-Expressing Tumors At ESMO 2023 Congress
Portfolio Pulse from Benzinga Newsdesk
Bolt Biotherapeutics (NASDAQ:BOLT) has presented updated data from its Phase 1 dose-escalation trial of BDC-1001 at the ESMO 2023 Congress. The data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose. BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate (ISAC) in development for the treatment of patients with HER2-positive cancer. The company plans to initiate Phase 2 dose-expansion clinical trial in patients with HER2-positive colorectal, breast, endometrial and gastric cancers.
October 23, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bolt Biotherapeutics has presented positive updated data from its Phase 1 trial of BDC-1001, supporting the selection of 20 mg/kg q2w as the recommended Phase 2 dose. This could potentially lead to a positive impact on the company's stock.
The positive updated data from the Phase 1 trial of BDC-1001 supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose. This indicates progress in the company's drug development, which could potentially lead to a positive impact on the company's stock as it shows the company's potential for growth and profitability in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100